Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
841 to 860 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities. | Molecules | 2023 | 36770884 | PubTator, text mining | PubMed |
| In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor. | Molecules | 2023 | 36770875 | PubTator, text mining | PubMed |
| Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma. | Int J Mol Sci | 2023 | 36768967 | PubTator, text mining | PubMed |
| Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives. | Cancers (Basel) | 2023 | 36765919 | PubTator, text mining | PubMed |
| Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α. | Cancers (Basel) | 2023 | 36765568 | PubTator, text mining | PubMed |
| Modulation of CaV1.2 Channel Function by Interacting Proteins and Post-Translational Modifications: Implications in Cardiovascular Diseases and COVID-19. | Handb Exp Pharmacol | 2023 | 36764970 | PubTator, text mining | PubMed |
| Advancing targeted protein degrader discovery by measuring cereblon engagement in cells. | Methods Enzymol | 2023 | 36764756 | PubTator, text mining | PubMed |
| Cereblon target validation using a covalent inhibitor of neosubstrate recruitment. | Methods Enzymol | 2023 | 36764755 | PubTator, text mining | PubMed |
| Structural mechanism of CRL4-instructed STAT2 degradation via a novel cytomegaloviral DCAF receptor. | EMBO J | 2023 | 36762436 | PubTator, text mining | PubMed |
| Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma. | Front Oncol | 2023 | 36761952 | PubTator, text mining | PubMed |
| Discovery of Highly Potent CRBN Ligands and Insight into Their Binding Mode through Molecular Docking and Molecular Dynamics Simulations. | ChemMedChem | 2023 | 36750890 | PubTator, text mining | PubMed |
| Piperlongumine conjugates induce targeted protein degradation. | Cell Chem Biol | 2023 | 36750097 | PubTator, text mining | PubMed |
| Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation. | J Med Chem | 2023 | 36749666 | PubTator, text mining | PubMed |
| Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. | Oncogene | 2023 | 36747009 | PubTator, text mining | PubMed |
| Glutamine synthetase expression rescues human dendritic cell survival in a glutamine-deprived environment. | Front Oncol | 2023 | 36741028 | PubTator, text mining | PubMed |
| Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy. | Adv Sci (Weinh) | 2023 | 36737841 | PubTator, text mining | PubMed |
| Screening of an epigenetic compound library identifies BRD4 as a potential antiviral target for hepatitis B virus covalently closed circular DNA transcription. | Antiviral Res | 2023 | 36737008 | PubTator, text mining | PubMed |
| Development of Human Carbonic Anhydrase II Heterobifunctional Degraders. | J Med Chem | 2023 | 36735827 | PubTator, text mining | PubMed |
| Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer. | Cancer Discov | 2023 | 36734633 | PubTator, text mining | PubMed |
| Lethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells. | Front Chem | 2023 | 36733715 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=43